Literature DB >> 10964709

A novel 31-amino-acid-length endothelin, ET-1(1-31), can act as a biologically active peptide for vascular smooth muscle cells.

N Nagata1, Y Niwa, Y Nakaya.   

Abstract

Human chymase produces a novel endothelin-1 with 31 amino-acid length ¿ET-1(1-31)¿, which is longer than conventional ET-1, ¿ET-1(1-21)¿. The aim of our study was to investigate the role of ET-1(1-31) on porcine coronary vascular smooth muscle cell (VSMC). Although the increase in [Ca(2+)](i) by ET-1(1-31) was 10 times weaker than that of ET-1(1-21), ET-1(1-31) showed equivalent potency in VSMC proliferation, c-fos/c-myc mRNA expression and cell cycle analysis with ET-1(1-21). ET-1(1-31) significantly induced expression of cyclin D1 but not those of cyclin D2 or D3. These effects were specifically inhibited by BQ485, an ET(A) receptor antagonist, although that of ET-1(1-21) was not specific to BQ485, suggesting different receptor specificity from ET-1(1-21). These results indicate that ET-1(1-31) also can involve a VSMC proliferation process such as atherosclerosis, although it has weaker vasoconstricting potency and different receptor subtypes on VSMC from those of ET-1(1-21). Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10964709     DOI: 10.1006/bbrc.2000.3292

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

Review 1.  The vascular endothelin system in hypertension--recent patents and discoveries.

Authors:  Meri M Hynynen; Raouf A Khalil
Journal:  Recent Pat Cardiovasc Drug Discov       Date:  2006-01

Review 2.  Mast cell tryptases and chymases in inflammation and host defense.

Authors:  George H Caughey
Journal:  Immunol Rev       Date:  2007-06       Impact factor: 12.988

Review 3.  Mast cell proteases as protective and inflammatory mediators.

Authors:  George H Caughey
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

4.  Vasoconstrictor activity of novel endothelin peptide, ET-1(1 - 31), in human mammary and coronary arteries in vitro.

Authors:  J J Maguire; R E Kuc; A P Davenport
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

5.  Pressor and pulmonary responses to ET-1(1-31) in guinea-pigs.

Authors:  Jean-Claude Honoré; Mirco Plante; Ghassan Bkaily; Giles A Rae; Pedro D'Orléans-Juste
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

6.  Big ET-1 processing into vasoactive peptides in arteries and veins.

Authors:  Stephanie W Watts; Keshari Thakali; Chuck Smark; Catherine Rondelli; Gregory D Fink
Journal:  Vascul Pharmacol       Date:  2007-09-07       Impact factor: 5.773

7.  Endothelin-1-induced venous contraction is maintained in DOCA-salt hypertension; studies with receptor agonists.

Authors:  Stephanie W Watts; Gregory D Fink; Carrie A Northcott; James J Galligan
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

8.  Effect of the haeme oxygenase-1/endogenous carbon monoxide system on atherosclerotic plaque formation in rabbits.

Authors:  Da-Nan Liu; Ying Fang; Li-Rong Wu; Xing-De Liu; Ping Li; Zuo-Yun He
Journal:  Cardiovasc J Afr       Date:  2010 Sep-Oct       Impact factor: 1.167

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.